newsfilter
← Latest News
GlobeNewswire·

Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights

– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance